A Case Series of Third‐Trimester Raltegravir Initiation: Impact on Maternal HIV‐1 Viral Load and Obstetrical Outcomes

Abstract

The present study provides preliminary data to support the use of RAL-containing cART to expedite HIV-1 VL reduction in women who have a high VL or suboptimal VL suppression late in pregnancy, and to decrease the risk of HIV perinatal transmission while avoiding Caesarean section. Further assessment of RAL safety during pregnancy is warranted.